Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. BMY rose 1.47% to $55.79 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to ...
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study
Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy ...
Treasury4d
Bristol Myers Squibb Lights the Way to Treasury Innovation
For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with ...
Bristol Myers Squibb GC to Retire After 33 years With Drugmaker
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...
PMLiVE5d
Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis
Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...
Pharmabiz5d
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...
appliedclinicaltrialsonline6d
Five-Year POETYK PSO Trial Results Show Sustained Efficacy, Safety with Sotyktu for Moderate-to-Severe Plaque Psoriasis
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...